Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

84 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
In the war against solid tumors arsenic trioxide needs partners.
Subbarayan PR, Ardalan B. Subbarayan PR, et al. Among authors: ardalan b. J Gastrointest Cancer. 2014 Sep;45(3):363-71. doi: 10.1007/s12029-014-9617-8. J Gastrointest Cancer. 2014. PMID: 24825822 Review.
The presence of three repeats in the 5' UTR region of thymidylate synthase (TS) is associated with increased TS mRNA expression in cultured human cancer cell lines in vitro.
Hammad H, Sarkar M, Gupta N, Ardalan B, Subbarayan PR. Hammad H, et al. Oncol Rep. 2012 Jan;27(1):246-9. doi: 10.3892/or.2011.1469. Epub 2011 Sep 22. Oncol Rep. 2012. PMID: 21947036
Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance.
Subbarayan PR, Sarkar M, Nelson G, Benitez E, Singhal S, Ardalan B. Subbarayan PR, et al. Anticancer Res. 2010 Apr;30(4):1149-56. Anticancer Res. 2010. PMID: 20530421
Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
Tiesi G, Park W, Gunder M, Rubio G, Berger M, Ardalan B, Livingstone A, Franceschi D. Tiesi G, et al. Among authors: ardalan b. J Surg Res. 2017 Aug;216:65-72. doi: 10.1016/j.jss.2017.03.022. Epub 2017 Mar 31. J Surg Res. 2017. PMID: 28807215
A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma.
Ardalan B, Subbarayan PR, Ramos Y, Gonzalez M, Fernandez A, Mezentsev D, Reis I, Duncan R, Podolsky L, Lee K, Lima M, Ganjei-Azar P. Ardalan B, et al. Clin Cancer Res. 2010 Jun 1;16(11):3019-27. doi: 10.1158/1078-0432.CCR-09-2590. Epub 2010 May 25. Clin Cancer Res. 2010. PMID: 20501625 Clinical Trial.
Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial.
Feun LG, O'Brien C, Molina E, Rodriguez M, Jeffers L, Schiff ER, Marini A, Savaraj N, Ardalan B. Feun LG, et al. J Cancer Res Clin Oncol. 2003 Jan;129(1):17-20. doi: 10.1007/s00432-002-0398-2. Epub 2003 Jan 9. J Cancer Res Clin Oncol. 2003. PMID: 12618896 Clinical Trial.
Cytotoxic effects and mechanisms of an alteration in the dose and duration of 5-fluorouracil.
Patel M, Ardalan K, Hochman I, Tian EM, Ardalan B. Patel M, et al. Anticancer Res. 2003 Jan-Feb;23(1A):447-52. Anticancer Res. 2003. PMID: 12680247
After 6 days from the initial exposure, the 10 microM/24 hour schedule (schedule A) inhibited more cell growth than the 100 microM/1 hour regimen (schedule B) by more than 38% and 17% in the two cell lines. After the 6-day observation, schedule A inhibited twice as much T. …
After 6 days from the initial exposure, the 10 microM/24 hour schedule (schedule A) inhibited more cell growth than the 100 microM/1 hour re …
A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer.
Ardalan B, Kozyreva O, Tsai KT, Santos E, Franceschi D, Livingstone A, Lima M. Ardalan B, et al. Anticancer Drugs. 2007 Sep;18(8):955-61. doi: 10.1097/CAD.0b013e3281430f8a. Anticancer Drugs. 2007. PMID: 17667602 Clinical Trial.
84 results
Jump to page
Feedback